|
1
|
Cancer incidence in Sweden in 2011.
National Board of Health and Welfare; Stockholm, Sweden: pp. 23–25.
2012
|
|
2
|
Haidopoulos D, Simou M, Akrivos N,
Rodolakis A, Vlachos G, et al: Risk factors in women 40 years of
age and younger with endometrial carcinoma. Acta Obstet Gynecol
Scand. 89:1326–1330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers and the implications for
pathogenesis, classification, and targeted therapies. Cancer
Control. 16:8–13. 2009.
|
|
5
|
Black D, Bogomolniy F, Robson ME, Offit K,
Barakat RR and Boyd J: Evaluation of germline PTEN mutations in
endometrial cancer patients. Gynecol Oncol. 96:21–24. 2005.
View Article : Google Scholar
|
|
6
|
Peterson LM, Kipp BR, Halling KC, et al:
Molecular characterization of endometrial cancer: a correlative
study assessing microsatellite instability, MLH1 hypermethylation,
DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and
BRAF mutation analysis. Int J Gynecol Pathol. 31:195–205. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olson SH, Chen C, De Vivo I, Doherty JA,
Hartmuller V, et al: Maximizing resources to study an uncommon
cancer: E2C2 - Epidemiology of Endometrial Cancer Consortium.
Cancer Causes Control. 20:491–496. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farooq A, Walker LJ, Bowling J and Audisio
RA: Cowden syndrome. Cancer Treat Rev. 36:577–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pilarski R, Burt R, Kohlman W, Pho L,
Shannon KM and Swisher E: Cowden syndrome and the PTEN hamartoma
tumor syndrome: systematic review and revised diagnostic criteria.
J Natl Cancer Inst. 105:1607–1616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et
al: Cancer risk and genotype-phenotype correlations in PTEN
hamartoma tumor syndrome. Fam Cancer. 13:57–63. 2014. View Article : Google Scholar
|
|
11
|
Bubien V, Bonnet F, Brouste V, et al;
French Cowden Disease Network. High cumulative risks of cancer in
patients with PTEN hamartoma tumour syndrome. J Med Genet.
50:255–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan MH, Mester JL, Ngeow J, Rybicki LA,
Orloff MS and Eng C: Lifetime cancer risks in individuals with
germline PTEN mutations. Clin Cancer Res. 18:400–407. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
National Comprehensive Cancer Network.
NCCN guidelines, version 1.2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Accessed September 25, 2012
|
|
14
|
Orloff MS and Eng C: Genetic and
phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Oncogene. 27:5387–5397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marsh DJ, Dahia PL, Caron S, et al:
Germline PTEN mutations in Cowden syndrome-like families. J Med
Genet. 35:881–885. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rustad CF, Bjørnslett M, Heimdal KR, Mæhle
L, Apold J and Møller P: Germline PTEN mutations are rare and
highly penetrant. Hered Cancer Clin Pract. 4:177–185. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lynch ED, Ostermeyer EA, Lee MK, et al:
Inherited mutations in PTEN that are associated with breast cancer,
cowden disease, and juvenile polyposis. Am J Hum Genet.
61:1254–1260. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Freihoff D, Kempe A, Beste B, et al:
Exclusion of a major role for the PTEN tumour-suppressor gene in
breast carcinomas. Br J Cancer. 79:754–758. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurian AW, Hare EE, Mills MA, et al:
Clinical evaluation of a multiple-gene sequencing panel for
hereditary cancer risk assessment. J Clin Oncol. 32:2001–2009.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Castéra L, Krieger S, Rousselin A, et al:
Next-generation sequencing for the diagnosis of hereditary breast
and ovarian cancer using genomic capture targeting multiple
candidate genes. Eur J Hum Genet. 22:1305–1313. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laugé A, Lefebvre C, Laurent-Puig P, et
al: No evidence for germline PTEN mutations in families with breast
and brain tumours. Int J Cancer. 84:216–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagy R, Ganapathi S, Comeras I, et al:
Frequency of germline PTEN mutations in differentiated thyroid
cancer. Thyroid. 21:505–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou XP, Waite KA, Pilarski R, et al:
Germline PTEN promoter mutations and deletions in
Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN
protein and dysregulation of the phosphoinositol-3-kinase/Akt
pathway. Am J Hum Genet. 73:404–411. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bennett KL, Mester J and Eng C: Germline
epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
JAMA. 304:2724–2731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ni Y, Zbuk KM, Sadler T, et al: Germline
mutations and variants in the succinate dehydrogenase genes in
Cowden and Cowden-like syndromes. Am J Hum Genet. 83:261–268. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Orloff MS, He X, Peterson C, et al:
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like
syndromes. Am J Hum Genet. 92:76–80. 2013. View Article : Google Scholar :
|
|
27
|
Ngeow J, Ni Y, Tohme R, Song Chen F, Bebek
G and Eng C: Germline alterations in RASAL1 in Cowden syndrome
patients presenting with follicular thyroid cancer and in
individuals with apparently sporadic epithelial thyroid cancer. J
Clin Endocrinol Metab. 99:E1316–E1321. 2014. View Article : Google Scholar : PubMed/NCBI
|
